Biogen Stock Hits Fresh High on Eli Lilly Buzz

Biogen stock is seeing increased optimism in response to the buzz

Deputy Editor
May 3, 2023 at 10:59 AM
facebook twitter linkedin

The shares of Biogen Inc (NASDAQ:BIIB) are enjoying tailwinds from positive news surrounding sector peer Eli Lilly's (LLY) Alzheimer's drug donanemab. Biogen last week reported first-quarter earnings and revenue that beat Wall Street's expectations, and recently received U.S. Food and Drug Administration (FDA) authorization for its ALS treatment drug Qalsody.

The stock was last seen 1.8% higher to trade at $314.96, and earlier touched a nearly two-year high of $316.69. BIIB's post-earnings pullback was saved by the $275 level and the 50-day moving average, and it's now up 51.9% over the last 12 months with a 12.8% year-to-date gain to boot.

Options traders are chiming in at triple the volume that's normally seen at this point. So far, 893 calls and 330 puts have crossed the tape. The most popular is the weekly 5/5 310-strike call.  

Mizuho is also bullish, raising its price target to $340 from $315. Coming into today, 20 of 27 covering brokerages rated Biogen stock a "buy" or better, while the 12-month average target price of $328.93 is a 5.2% premium to its current perch.


Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!